ATE460901T1 - Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut - Google Patents

Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut

Info

Publication number
ATE460901T1
ATE460901T1 AT04796413T AT04796413T ATE460901T1 AT E460901 T1 ATE460901 T1 AT E460901T1 AT 04796413 T AT04796413 T AT 04796413T AT 04796413 T AT04796413 T AT 04796413T AT E460901 T1 ATE460901 T1 AT E460901T1
Authority
AT
Austria
Prior art keywords
drug
skin
core
bioerodible
polymer
Prior art date
Application number
AT04796413T
Other languages
English (en)
Inventor
Kang-Jye Chou
Hong Guo
Paul Ashton
Robert Shimizu
David Watson
Original Assignee
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/714,549 external-priority patent/US8871241B2/en
Application filed by Psivida Inc filed Critical Psivida Inc
Application granted granted Critical
Publication of ATE460901T1 publication Critical patent/ATE460901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Prostheses (AREA)
AT04796413T 2003-11-13 2004-10-26 Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut ATE460901T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/714,549 US8871241B2 (en) 2002-05-07 2003-11-13 Injectable sustained release delivery devices
US54336804P 2004-02-09 2004-02-09
PCT/US2004/035430 WO2005051234A2 (en) 2003-11-13 2004-10-26 Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Publications (1)

Publication Number Publication Date
ATE460901T1 true ATE460901T1 (de) 2010-04-15

Family

ID=34636703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04796413T ATE460901T1 (de) 2003-11-13 2004-10-26 Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut

Country Status (20)

Country Link
EP (2) EP1696822B1 (de)
JP (3) JP5661226B2 (de)
AT (1) ATE460901T1 (de)
AU (1) AU2004292957C1 (de)
CA (1) CA2545650C (de)
CY (1) CY1114947T1 (de)
DE (1) DE602004026106D1 (de)
DK (1) DK1696822T3 (de)
ES (2) ES2447816T7 (de)
FR (1) FR14C0042I1 (de)
HK (1) HK1148931A1 (de)
IL (1) IL175584A (de)
MX (1) MXPA06005431A (de)
NO (1) NO20062362L (de)
NZ (3) NZ547619A (de)
PL (2) PL1696822T3 (de)
PT (2) PT1696822E (de)
SI (1) SI1696822T1 (de)
TW (2) TWI496597B (de)
WO (1) WO2005051234A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
NZ547619A (en) 2003-11-13 2009-06-26 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
EP1765454B1 (de) 2004-07-02 2016-04-13 Mati Therapeutics Inc. Behandlungsmittelabgabevorrichtung für das auge
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
KR101062796B1 (ko) * 2006-03-31 2011-09-06 큐엘티 인코포레이티드 약물 요법을 위한 비루관 배출계 임플란트
CN101784263B (zh) 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂
CN101861135A (zh) 2007-09-07 2010-10-13 Qlt栓塞输送公司 泪道植入物检测
FR2927798B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de fabrication d'un dispositif contraceptif intra-uterin et installation pour la mise en oeuvre de ce procede
US20100278895A1 (en) 2009-04-30 2010-11-04 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
EP2515864A4 (de) * 2009-12-23 2013-09-11 Psivida Inc Vorrichtung mit verzögerter freisetzung
JP2013523821A (ja) * 2010-04-06 2013-06-17 アラーガン、インコーポレイテッド 前房内薬剤送達のための徐放性リザーバーインプラント
WO2011146483A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8911427B2 (en) * 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
AU2012214146A1 (en) * 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2846384C (en) 2011-08-29 2020-12-15 Qlt Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EA201490500A1 (ru) 2011-08-30 2014-06-30 Университейт Гент Многослойный высвобождающий состав
EP2854890B1 (de) * 2012-05-30 2019-02-06 Boston Scientific Scimed, Inc. Injizierbare biologisch abbaubare partikel zur gesteuerten wirkstofffreisetzung
AU2015366355B2 (en) * 2014-12-18 2020-05-28 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
US11298323B2 (en) * 2017-06-13 2022-04-12 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
FR3085841B1 (fr) * 2018-09-14 2020-12-04 Oreal Procede de preparation de capsules et systeme associe
EP3698841A1 (de) * 2019-02-19 2020-08-26 L'oreal Injektionsvorrichtung
CA3171147A1 (en) * 2020-03-17 2021-09-23 Nannaji Saka Expandable, multi-excipient structured dosage form for prolonged drug release

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5486328A (en) 1994-05-31 1996-01-23 Randcastle Extrusion Systems, Inc. Extrusion surge suppressor and method
US5518672A (en) 1994-05-31 1996-05-21 Randcastle Extrusion Systems, Inc. Extrusion surge controller and method
US5569429A (en) 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
SE0001893D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical arrangement
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
WO2003051328A1 (en) * 2001-12-18 2003-06-26 Novo Nordisk A/S Solid dose micro implant
NZ547619A (en) 2003-11-13 2009-06-26 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Also Published As

Publication number Publication date
EP1696822A2 (de) 2006-09-06
DE602004026106D1 (de) 2010-04-29
CA2545650A1 (en) 2005-06-09
EP2233112A3 (de) 2011-03-02
NZ547619A (en) 2009-06-26
AU2004292957A1 (en) 2005-06-09
ES2447816T7 (es) 2014-06-25
IL175584A0 (en) 2006-09-05
EP1696822B1 (de) 2010-03-17
JP2014040479A (ja) 2014-03-06
NO20062362L (no) 2006-08-13
AU2004292957C1 (en) 2011-04-28
NZ581461A (en) 2011-04-29
PL1696822T3 (pl) 2010-08-31
NZ575950A (en) 2010-06-25
JP2012072180A (ja) 2012-04-12
PL2233112T6 (pl) 2014-11-28
WO2005051234A3 (en) 2005-11-10
TWI445559B (zh) 2014-07-21
ES2340389T3 (es) 2010-06-02
EP2233112A2 (de) 2010-09-29
PT2233112E (pt) 2014-02-27
JP5661226B2 (ja) 2015-01-28
TW200526285A (en) 2005-08-16
IL175584A (en) 2015-05-31
JP5526114B2 (ja) 2014-06-18
JP5918195B2 (ja) 2016-05-18
PL2233112T3 (pl) 2014-05-30
PT1696822E (pt) 2010-04-28
JP2007512248A (ja) 2007-05-17
WO2005051234A2 (en) 2005-06-09
SI1696822T1 (sl) 2010-07-30
DK1696822T3 (da) 2010-05-17
HK1148931A1 (en) 2011-09-23
CA2545650C (en) 2015-08-18
FR14C0042I1 (fr) 2014-06-27
EP2233112B3 (de) 2014-05-14
MXPA06005431A (es) 2007-01-25
AU2004292957B2 (en) 2010-09-09
ES2447816T3 (es) 2014-03-13
EP2233112B1 (de) 2013-11-20
CY1114947T1 (el) 2016-12-14
TW201422269A (zh) 2014-06-16
TWI496597B (zh) 2015-08-21

Similar Documents

Publication Publication Date Title
HK1148931A1 (en) Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
AU651084B2 (en) Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
WO2005009408A3 (en) Sustained release dosage forms of anesthetics for pain management
Teoh et al. Fabricating scalable, personalized wound dressings with customizable drug loadings via 3D printing
DE602004019224D1 (de) Herstellung von langzeit-arzneimittelabgabevorrichtungen mit polymeren auf polyurethanbasis
FR2764514B1 (fr) Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
WO2002064193A3 (en) Microneedle devices and production thereof
CA2543617A1 (en) Preparing active polymer extrudates
IL201746A (en) Membrane shell of a transplantable mating system
WO2011012137A3 (en) A medical device of polyolefin
Johnson et al. Drug eluting implants in pharmaceutical development and clinical practice
Masood Application of fused deposition modelling in controlled drug delivery devices
EP3723725B1 (de) Mikronadelarray aufweisend einen wirkstoff in form von salzen
CA2386217A1 (en) Bioengineered collagen fibrils
ATE398447T1 (de) Verwendung von ethanol als weichmacher zur herstellung von subkutanen implantaten , welche in einer plga matrize dispergierte thermolabile wirkstoffe enthalten
KR20130133572A (ko) 미세바늘 어레이 기판 및 제조 방법
KR101460499B1 (ko) 마이크로니들 디바이스의 제조방법
IN2012DN04939A (de)
CY1114534T1 (el) Συσκευες ενεσιμης χορηγησης με παρατεταμενη αποδεσμευση
EP2558271A1 (de) Kanülenvorrichtung und verfahren und vorrichtung zum bestücken einer kanülenvorrichtung mit einem implantat
CN1209169C (zh) 医用外科固定材料及其制备方法
Govender et al. 3D bioprinted microneedles: merging drug delivery and scaffold science for tissue-specific applications
WO2023032118A1 (ja) マイクロニードル、マイクロニードルアレイ及びマイクロニードルパッチ並びにマイクロニードルアレイの製造方法
Somwanshi et al. Natural Alternatives to Non-biodegradable Polymers in 3D Printing of Pharmaceuticals
SHKARA et al. 3D Printing in Pharmaceutics: Role of Fused Deposition Modelling (FDM) in Drug Delivery.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1696822

Country of ref document: EP